Allogeneic transplantation of hematopoietic cells is an effective treatment of leukemia, even
in advanced stages. Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) …

Despite therapeutic progress in acute myeloid leukemia (AML), relapse post-allogeneic
hematopoietic stem cell transplantation (allo-HSCT) remains a major challenge. Here, we …

BACKGROUND: Treatment of relapsed hematological malignancies after an allogeneic
peripheral blood stem cell transplant (SCT) is challenging. Donor lymphocyte infusion (DLI) …

Allogeneic haematological stem cell transplantation (HSCT) has developed into
immunotherapy. Donor CD4+, CD8+ and natural killer (NK) cells have been reported to …

Introduction: Allogeneic hematopoietic stem cell transplantation (SCT) is the treatment of
choice for many malignant hematological disorders. Following recent improvements in non …

Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the
treatment of several malignant and not malignant hematological diseases. However, relapse …

Highlights•Donor lymphocyte infusion (DLI) provides a way to enhance the graft-versus-
leukemia effect.•GvHD represents the main toxicity after DLI.•Pre-DLI low disease burden …

The efficacy and safety of donor-derived anti-CD19 CAR T cells vs DLI for the management
of relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allo-hematopoietic stem cell …

Allogeneic stem cell transplantation (SCT) offers the only hope for cure for many adults with
acute leukemia. Unfortunately, many patients relapse and die of their disease even after …

Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML)
relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain …